




RealRate

PHARMACEUTICAL 2021

ACELRX PHARMACEUTICALS INC
Rank 274 of 409

AcelRx
Pharmaceuticals, Inc.



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

ACELRX PHARMACEUTICALS INC Rank 274 of 409



The relative strengths and weaknesses of ACELRX PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ACELRX PHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 79% points. The greatest weakness of ACELRX PHARMACEUTICALS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is -239%, being 116% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 46,830 |
| Cost of Goods Sold | 6,032 |
| Intangible Assets | 0 |
| Liabilities, Current | 17,635 |
| Liabilities, Non-Current | 16,045 |
| Other Assets | 3,806 |
| Other Compr. Net Income | 0 |
| Other Expenses | 4.0 |
| Other Liabilities | 88,365 |
| Other Net Income | 588 |
| Property and Equipment | 15,659 |
| Research and Development | 4,017 |
| Revenues | 5,416 |
| Selling, General and Administrative Expense | 36,330 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 66,295 |
| Liabilities | 122,045 |
| Expenses | 46,383 |
| Stockholders Equity | -55,750 |
| Net Income | -40,379 |
| Comprehensive Net Income | -40,379 |
| Economic Capital Ratio | -239% |

